Allergan Bolsters Botox Biz With Medy-Tox Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma is highly protective of its slot as the market leader in neuro modulators and has been working to add indications, as well as conduct deals that can help it retain its position with its Botox franchise.
You may also be interested in...
Allergan Buys MAP To Chart Migraine Franchise Growth
Allergan partnered with MAP in 2011 for rights to commercialize Levadex for acute migraine in North America, but now will control 100% of the product’s revenue, creating a complementary product to Botox in chronic migraine. Levadex has an April 15 PDUFA date at FDA.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: